Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junia V Melo

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Oncotargets and Therapy|July 10, 2010
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinibCharles Chuah, Junia V Melo
Blood|August 2, 2002
Acquired resistance to imatinib mesylate: selection for pre-existing mutant cellsLucio Luzzatto, Junia V Melo
Hematology. American Society of Hematology. Education Program|December 17, 2008
Novel agents in CML therapy: tyrosine kinase inhibitors and beyondJunia V Melo, Charles Chuah
Annals of Hematology|March 28, 2015
Natural course and biology of CMLBradley Chereda, Junia V Melo
International Journal of Hematology|July 9, 2004
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant diseaseChikashi Yoshida, Junia V Melo
Clinical Hematology International|October 1, 2021
One Year into the COVID-19 PandemicMohamad Mohty, Junia V Melo
Clinical Hematology International|February 6, 2025
How to perform a high-quality peer reviewMohamad Mohty, Junia V Melo
Cancer Letters|September 5, 2006
Resistance to imatinib mesylate in chronic myeloid leukaemiaJunia V Melo, Charles Chuah
Clinical Hematology International|March 20, 2023
Another Year to Celebrate Advances in Clinical HematologyMohamad Mohty, Junia V Melo
Acta Haematologica|November 15, 2002
Cytogenetic and molecular genetic aspects of chronic myeloid leukaemiaDavid J Barnes, Junia V Melo
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Oncotargets and Therapy|July 10, 2010
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinibCharles Chuah, Junia V Melo
Blood|August 2, 2002
Acquired resistance to imatinib mesylate: selection for pre-existing mutant cellsLucio Luzzatto, Junia V Melo
Hematology. American Society of Hematology. Education Program|December 17, 2008
Novel agents in CML therapy: tyrosine kinase inhibitors and beyondJunia V Melo, Charles Chuah
Annals of Hematology|March 28, 2015
Natural course and biology of CMLBradley Chereda, Junia V Melo
International Journal of Hematology|July 9, 2004
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant diseaseChikashi Yoshida, Junia V Melo
Clinical Hematology International|October 1, 2021
One Year into the COVID-19 PandemicMohamad Mohty, Junia V Melo
Clinical Hematology International|February 6, 2025
How to perform a high-quality peer reviewMohamad Mohty, Junia V Melo
Cancer Letters|September 5, 2006
Resistance to imatinib mesylate in chronic myeloid leukaemiaJunia V Melo, Charles Chuah
Clinical Hematology International|March 20, 2023
Another Year to Celebrate Advances in Clinical HematologyMohamad Mohty, Junia V Melo
Acta Haematologica|November 15, 2002
Cytogenetic and molecular genetic aspects of chronic myeloid leukaemiaDavid J Barnes, Junia V Melo
Pageof 9